menu
    • menu
    [{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Evofem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bora Pharmaceuticals \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Bora Pharmaceuticals \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Kyowa Pharmaceutical Industry","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Bora Pharmaceuticals \/ Bora Pharmaceutical Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Bora Pharmaceuticals \/ Bora Pharmaceutical Laboratories"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"TaiRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Foslinanib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bora Pharmaceuticals \/ TaiRx","highestDevelopmentStatusID":"8","companyTruncated":"Bora Pharmaceuticals \/ TaiRx"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Upsher-Smith Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bora Pharmaceuticals","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.20999999999999999,"dosageForm":"Capsule","sponsorNew":"Bora Pharmaceuticals \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Bora Pharmaceuticals \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Upsher-Smith Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.20999999999999999,"dosageForm":"Capsule","sponsorNew":"Bora Pharmaceuticals \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Bora Pharmaceuticals \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"CT-G20","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bora Pharmaceuticals \/ Celltrion","highestDevelopmentStatusID":"6","companyTruncated":"Bora Pharmaceuticals \/ Celltrion"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Pyros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Vigabatrin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bora Pharmaceuticals \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Bora Pharmaceuticals \/ Bora Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Bora Pharmaceuticals

    Menu

    Bora Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    Key Services KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bora Pharmaceuticals

                            Taiwan
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothBora Pharmaceuticals- Making success more certain.

                            Lead Product(s) : Vigabatrin

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Pyros Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Bora Expands Rare Disease Portfolio with Pyros Pharma Acquisition

                            Details : Through the acquisition of US-based Pyros, Bora will expand his pipelines by adding some candidates such as Vigafyde (vigabatrin), which is indicated for the treatment of infantile spasms.

                            Brand Name : Vigafyde

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 25, 2024

                            Lead Product(s) : Vigabatrin

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Pyros Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            Bora Pharmaceutical

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bora Pharmaceuticals

                            Taiwan
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothBora Pharmaceuticals- Making success more certain.

                            Lead Product(s) : Amantadine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Upsher-Smith Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Bora Pharmaceuticals Completes Acquisition of Upsher-Smith

                            Details : Through the acquisition, Bora will commercialize Amantadine HCl-Generic, which is an NMDA receptor inhibitor. It is indicated for the treatment of influenza A infections and Parkinsonism.

                            Brand Name : Amantadine HCl-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 01, 2024

                            Lead Product(s) : Amantadine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Upsher-Smith Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            Bora Pharmaceutical

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bora Pharmaceuticals

                            Taiwan
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothBora Pharmaceuticals- Making success more certain.

                            Lead Product(s) : Amantadine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Upsher-Smith Laboratories

                            Deal Size : $210.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            CDMO Bora Pharmaceuticals Buys Generics Manufacturer Upsher-Smith for $210M

                            Details : Bora acquires Upsher-Smith’s product portfolio, including Amantadine hydrochloride for treating influenza A virus infections.

                            Brand Name : Amantadine HCl-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 18, 2024

                            Lead Product(s) : Amantadine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Upsher-Smith Laboratories

                            Deal Size : $210.0 million

                            Deal Type : Acquisition

                            Bora Pharmaceutical

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bora Pharmaceuticals

                            Taiwan
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothBora Pharmaceuticals- Making success more certain.

                            Lead Product(s) : CT-G20

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Celltrion

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bora and Celltrion Join Forces To Distribute Oral Drugs Across APAC

                            Details : Under the partnership, Bora will manufacture and commercialize a range of oral dosage form drugs (OSD), including CT-G20, a hypertrophic cardiomyopathy treatment candidate, across the APAC region.

                            Brand Name : CT-G20

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 06, 2023

                            Lead Product(s) : CT-G20

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Celltrion

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            Bora Pharmaceutical

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bora Pharmaceuticals

                            Taiwan
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothBora Pharmaceuticals- Making success more certain.

                            Lead Product(s) : Foslinanib,Sorafenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : TaiRx

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bora Pharmaceuticals Partners with TaiRx

                            Details : CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific fact...

                            Brand Name : CVM-1118

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 27, 2022

                            Lead Product(s) : Foslinanib,Sorafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : TaiRx

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            Bora Pharmaceutical

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bora Pharmaceuticals

                            Taiwan
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothBora Pharmaceuticals- Making success more certain.

                            Lead Product(s) : L-Lactic Acid,Citric Acid,Potassium Bitartrate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Recipient : Evofem Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Servi...

                            Details : Initially, Bora will manufacture Phexxi for nations currently considering formal regulatory approval of Phexxi (L-lactic Acid), for the prevention of pregnancy, including Mexico and Nigeria.

                            Brand Name : Phexxi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 10, 2022

                            Lead Product(s) : L-Lactic Acid,Citric Acid,Potassium Bitartrate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Recipient : Evofem Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            Bora Pharmaceutical

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Bora Pharmaceuticals

                            Taiwan
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothBora Pharmaceuticals- Making success more certain.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Undisclosed

                            Recipient : Kyowa Pharmaceutical Industry

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to Manufacture Generic Product for F...

                            Details : Upon PMDA’s approval, Bora will be the commercial manufacturing site for the generic product production. Bora Pharmaceuticals’ sites already have an excellent track record with many regulatory agencies around the world.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 05, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Undisclosed

                            Recipient : Kyowa Pharmaceutical Industry

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            Bora Pharmaceutical

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth